Modeling of Xerostomia After Radiotherapy for Head and Neck Cancer: A Registry Study

Eva Onjukka1,2,*, Claes Mercke2,3, Einar Björgvinsson3, Anna Embring2,3, Anders Berglund4, Gabriella Alexandersson von Döbeln5, Signe Friesland2,3, Giovanna Gagliardi1, Clara Lenneby Helleday3, Helena Sjödin3 and Ingmar Lax1

1 Medical Radiation Physics and Nuclear Medicine, Karolinska University Hospital, Stockholm, Sweden, 2 Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden, 3 Department of Oncology, Karolinska University Hospital, Stockholm, Sweden, 4 Epistat Epidemiology and Statistics Consulting, Uppsala, Sweden

Aim: Data from a local quality registry are used to model the risk of late xerostomia after radiotherapy for head and neck cancer (HNC), based on dosimetric- and clinical variables. Strengths and weaknesses of using quality registry data are explored.

Methods: HNC patients treated with radiotherapy at the Karolinska University hospital are entered into a quality registry at routine follow up, recording morbidity according to a modified RTOG/LENT-SOMA scale. Other recorded parameters are performance status, age, gender, tumor location, tumor stage, smoking status, chemotherapy and radiotherapy data, including prescribed dose and organ-at-risk (OAR) dose. Most patients are entered at several time points, but at variable times after treatment. Xerostomia was modeled based on follow-up data from January 2014 to October 2018, resulting in 753 patients. Two endpoints were considered: maximum grade ≥2 (XERG≥2) or grade ≥3 (XERG≥3) late xerostomia. Univariate Cox regression was used to select variables for two multivariate models for each endpoint, one based on the mean dose to the total parotid volume (Dtot) and one based on the mean dose to the contralateral parotid (Dcontra). Cox regression allows the estimation of the risk of xerostomia at different time points; models were presented visually as nomograms estimating the risk at 9, 12, and 24 months respectively.

Results: The toxicity rates were 366/753 (49%) for XERG≥2 and 40/753 (5.3%) for XERG≥3. The multivariate models included several variables for XERG≥2, and dose, concomitant chemotherapy and age were included for XERG≥3. Induction chemotherapy and an increased number of fractions per week were associated with a lower risk of XERG≥2. However, since the causality of these relationships have limited support from previous studies, alternative models without these variables were also presented. The models based on the mean dose to the total parotid volume and the contralateral parotid alone were very similar.
INTRODUCTION

Radiotherapy contributes to favorable control of disease in the great majority of patients with head and neck cancer (HNC) and will certainly remain one of the prominent integral components in the multidisciplinary management of this disease. Approximately 80% of the patients receive radiotherapy at least once during the course of their disease (1). Even with great advances in radiotherapy planning facilitating a tailored delivery of radiation dose, some damage will be inflicted on normal cells in tissues adjacent to the tumor. The treatment of HNC is associated with clinically significant radiation-induced toxicity, especially in combination with concurrent systemic agents, chemotherapy or biomodulators (2, 3).

One of the most frequently reported side effects is hyposalivation, and subsequent xerostomia, due to co-irradiation of the salivary glands. Chronic xerostomia is a multifactorial process which can affect quality of life profoundly. The process includes reduced salivary output, decreased salivary pH and increased viscosity of the saliva (4, 5). This may result in the unpleasant sensation of dry mouth, altered taste, dysfunction of mastication, swallowing dysfunction and difficulties with speech (6–8). Xerostomia is also associated with changes in the normal flora of the mouth, which increases the risk of oral infections including dental caries (9). The reported prevalence of xerostomia in the normal population ranges from 5.5 to 46% (10). It increases with age, partly due to the frequent use of multiple medications by the elderly (11, 12). In a retrospective study including over 12,000 dental patients, predictors for patient-reported xerostomia were intake of more medications, recreational drug use, rheumatic diseases, psychiatric diseases, eating disorders and radiotherapy (10). Thus, the risk of xerostomia in patients undergoing radiotherapy for HNC is dependent on clinical factors as well as the radiation dose.

The incidence of HNC is currently on the rise as more patients suffer from an HPV-related tumor, predominantly in the oropharynx. These patients have a good prognosis with respect to tumor control and will have to live a long life with potential treatment-related side effects. It is therefore of utmost importance to clarify further the dose/volume-response relationship, also for lower grades of radiation-induced xerostomia. The introduction of new, more conformal, techniques such as intensity-modulated radiotherapy (IMRT) has reduced the rate of xerostomia both with respect to measurement of saliva flow and quality of life. There is a consensus that xerostomia is sufficiently limited by keeping the mean dose to the total parotid volume below 26 Gy as a planning criterion (13). However, as this criterion is frequently violated in order to achieve adequate tumor coverage, the rate of xerostomia in HNC patients is still a concern (14). Also, the relative importance of each parotid gland for preserved salivary function is unclear (15).

Evidence-based radiotherapy requires models which can be used for treatment planning, based on representative datasets. It has been recognized that such models need to be continuously validated and updated (16, 17) as treatment protocols and patient populations evolve (16). For this purpose, registries of outcome data need to be implemented, maintained and analyzed; the limited size of datasets historically used for model fitting, and the homogeneous nature of the data provided by controlled clinical trials, put into question the applicability of these models as decision-support tools in clinical practice. Also, one or a few fixed follow-up times are considered, not considering the risk of toxicity as a function of time. In the current study, Cox regression, where the endpoint is time to event, is used and thus the risk of xerostomia at any time point after treatment can be estimated. To the best of our knowledge, this is the first model of this type developed for xerostomia.

In this registry study, a multivariate model of xerostomia is fitted using clinical-, patient-, and treatment-related parameters in an effort to better predict both more severe but also moderate grades of xerostomia in the individual patient. The real-world nature of the collected data, and the size of the dataset, are favorable for the application of the model as a decision-support tool when treating HNC patients. The risk of modeling indirect relationships, given the unavoidably heterogeneous registry data, is carefully considered in the choice of model, variable selection method and interpretation of the results.

MATERIALS AND METHODS

Quality Registry

Head and neck cancer patients who are treated with radiotherapy at the Karolinska University Hospital, either radically or postoperatively with or without chemotherapy, are followed up after their therapy according to local protocols every third to fourth month during the first 2 years and thereafter every 6 months for an additional 3 years. Since 2013, clinical follow-up data, as well as patient- and treatment-related parameters are entered into a quality-registry database for all patients. A modified Radiation Therapy Oncology Group (RTOG)/LENT-SOMA scale is used for skin-, mucosa-, larynx- and mandible toxicity as well as xerostomia, dysphagia and trismus. Morbidity appearing within 3 months of completed radiotherapy is categorized as acute while morbidity appearing...
later is categorized as late. Performance status evaluated according to WHO/ECOG/ZUBROD is also registered at every follow-up visit. Patient-related parameters collected are: gender, age, tumor location, tumor stage, HPV association (for patients with cancer in the oropharynx) and smoking status at the time of treatment. The treatment parameters collected are: data on induction chemotherapy, concomitant drug therapy as well as prescribed dose and organ-at-risk (OAR) dose.

Informed consent regarding participation in the quality registry, including in the publication of analyzed data, is obtained from each patient. The study was approved by the regional ethics committee (2016/268-31/1).

**Patients**

The patients included in this study had histologically confirmed HNC originating in and categorized as cancer of the oral cavity, oropharynx or other (epipharynx, hypopharynx, nasal cavity, paranasal sinuses or metastases in the neck with an unknown primary). Patients with a tumor location associated with very low parotid dose were excluded (larynx, lip and basalioma) and tumors in the parotid were excluded since these patients can only be considered to have one single parotid as OAR.

None of the included patients had previous head and neck radiotherapy or previous malignancy except non-melanoma skin cancer. Radiotherapy was prescribed curatively, alone or with induction chemotherapy and/or concomitant cisplatin or cetuximab. Cisplatin was prescribed according to the estimated prescribed dose and organ-at-risk (OAR). 

Baseline (before radiotherapy) xerostomia scores were not available in this study. Thus, all endpoints reflect the overall xerostomia status after treatment, not exclusively relating to the treatment.

**Treatment**

External-beam radiotherapy was delivered with a linear accelerator using 6 MV photons. Twenty-five percent of the patients were treated with a combination of external-beam and brachy radiotherapy. The majority of the external-beam treatments were delivered with IMRT but 7% received 3D-conformal radiotherapy. During treatment planning the parotid glands and larynx were considered the primary OAR followed by swallowing structures; target coverage had the highest priority. Target volumes for primary tumor and regional nodal groups at risk of harboring occult metastatic disease, as well as OAR, were delineated according to departmental guidelines, which also include dose constraints. Specifically, the parotids were delineated as the entire gland as visible in the CT images, including both the deep lobe and the superficial lobe.

Prescribed dose to the primary target volume was; >73 Gy in 12%, 68 Gy in 69%, 66 Gy in 8%, and 50 Gy in 9%. The dose per fraction was 2.2 Gy for the highest dose group and 2.0 Gy for the other groups. Fifty-one percent of the patients were treated with six fractions per week and 45% received five fractions per week.

The dose per fraction to elective volumes was 2.0 Gy or 1.52 Gy when treating with a sequential- and simultaneous-integrated boost, respectively.

In this study, the mean dose to ipsilateral- and contralateral parotid glands separately, as well as the mean dose for the two glands together was considered, from the external-beam radiotherapy only. A separate investigation, made on a limited number of patients, showed that the contribution to the parotid mean dose from brachytherapy was negligible for modeling purposes (95%-percentile: 1.5 Gy).

**Modeling**

Since the time to the registered score varied from patient to patient, multivariate Cox regression models were developed. For each endpoint, the time to event was defined as the interval between the end of radiotherapy and the first score exceeding the respective threshold. Hazard ratios and nomograms were produced for each model. A bootstrap validation with 1000 samples was performed and the mean C-statistic over the bootstrap samples was used as a measure of model performance. Calibration was performed using bootstrap cross validation with 100 bootstrap samples, as described in (18), using Harrell’s R packages. All analyses were performed in R.

The candidate explanatory variables were: mean dose to the total parotid volume (D_{tot}), mean dose to the contralateral parotid (D_{contra}), mean dose to the ipsilateral parotid (D_{ipsi}), number of treatment fractions per week, tumor location, T stage, N stage, smoking status, induction chemotherapy, concomitant chemotherapy, gender and age. Two alternative models, based on D_{tot} and D_{contra}, respectively, were considered. This dose variable was forced into the model, irrespective of the univariate significance for the endpoint, and D_{ipsi} was only a candidate variable for the D_{contra} model, to avoid direct dependence between variables. For each model, the candidate variables with p ≤ 0.2 in a univariate analysis were considered in the multivariate analysis, while an alpha value of 0.05 was used in the multivariate analysis. Categorical variables were considered significant if at least half of the groups passed the alpha value.

Given the lack of register-data analyses available for comparison, and that only internal validation was possible, an alternative selection of variables was made following the
univariate analysis, excluding any variables with no/limited support in the literature with regard to their contribution to the risk of xerostomia. These variables were induction chemotherapy and the number of treatment fractions per week.

RESULTS

Patients

Out of the 753 patients included in the analysis, there were 366 (49%) with grade ≥ 2 late xerostomia and 40 (5.3%) with grade ≥ 3 late xerostomia. The median follow-up was 363 days and 292 days for XER_{G_2} and XER_{G_3} respectively. Table 1 lists the descriptive statistics.

| TABLE 1 | Patient- and treatment characteristics. |
|-------------------|-------------------|-------------------|
| Patients          | %                 |                  |
| Mean parotid dose |                  |                  |
| D_{tot} (Gy); mean (SD) | 26.2 (8.2) |                  |
| D_{contra} (Gy); mean (SD) | 17.7 (7.2) |                  |
| D_{ipsi} (Gy); mean (SD) | 34.8 (13) |                  |
| Fractions per week |                  |                  |
| 5                  | 294               | 39               |
| 6                  | 437               | 58               |
| 10                 | 22                | 2.9              |
| Age (years); mean (SD) | 61.4 (11.4) |                  |
| Gender             |                  |                  |
| Female             | 249               | 33               |
| Male               | 504               | 67               |
| Tumor location     |                  |                  |
| Oral cavity       | 172               | 23               |
| Oropharynx        | 443               | 59               |
| Other              | 138               | 18               |
| T stage            |                  |                  |
| 0                  | 40                | 5.3              |
| 1                  | 174               | 23               |
| 2                  | 289               | 36               |
| 3                  | 108               | 14               |
| 4                  | 142               | 19               |
| N stage            |                  |                  |
| 0                  | 252               | 34               |
| 1                  | 85                | 11               |
| 2a/b               | 348               | 46               |
| 2c                 | 61                | 8.1              |
| 3                  | 7                 | 0.9              |
| Smoking            |                  |                  |
| No/never           | 299               | 40               |
| Smoker             | 152               | 20               |
| Previous           | 302               | 40               |
| Concomitant chemotherapy |      |                  |
| Cisplatin          | 254               | 34               |
| ERBIT              | 206               | 27               |
| No                 | 293               | 39               |
| Induction chemotherapy |            |                  |
| Yes                | 203               | 27               |
| No                 | 550               | 73               |

Univariate Analysis

The results from the univariate analysis (hazard ratios and p-values) are listed in Supplementary Table A1 in the Supplementary Material, where the variables considered in the multivariate analysis are highlighted in bold. The main dose variable (D_{tot} or D_{contra}) did not consistently obtain low p-values but according to the chosen model selection strategy, this variable was still included in the multivariate model. More variables were significant for grade ≥ 2 xerostomia than for ≥ 3 xerostomia. This might be due to the fewer events of high-grade xerostomia in the population.

Radiotherapy technique (3D-conformal vs. IMRT) was not considered as an explanatory variable since any effect would be indirect, through cross-correlation with the volume of exposed parotid. However, its association with xerostomia was nonetheless tested in the univariate analysis. Surprisingly, as seen in Supplementary Table A1, the risk of xerostomia was significantly reduced in the small group of patients with 3D-conformal radiotherapy; these patients were typically treated for unilateral targets and received a lower target dose, as well as a lower D_{tot}.

Multivariate Analysis

Two multivariate models were fitted to each endpoint, one based on D_{tot} and one on D_{contra}; in a second step the models were refitted to only the variables associated with p < 0.05 in the initial multivariate model – see Table 2. The models are well calibrated – see calibration plots in Figure 1.

XER_{G_3} showed a positive dependence on dose, as opposed to XER_{G_2}, and the performance of this model was better. The dose variable was not statistically significant in all models but many non-dosimetric variables were significant, especially in the models for XER_{G_2}. The models based on D_{tot} and D_{contra} were very similar.

Given the explorative nature of the above analysis, an alternative variable selection method was also applied for the multivariate analysis by excluding any non-consensus variables. While in Table 2 the models revealed a lower risk of XER_{G_2} for patients with an accelerated treatment schedule and induction chemotherapy, the causality in these relationships might be controversial. Thus, the XER_{G_2} models were refitted, excluding the number of fractions per week and induction chemotherapy – see Table 3. As two variables were excluded the performance of the models reduced somewhat. The calibration plots are shown in Figure 2.

Since the models for XER_{G_2} had an inverse dose-response these are not suitable as decision support tools. Instead, Figure 3 shows a nomogram where dose was not forced into the model (for model specifics and the calibration plot, see Supplementary Table A2 and Supplementary Figure A1 in the Supplementary Material). Figure 4 shows the nomogram for XER_{G_3} corresponding to the model listed in Table 2. Please refer to the Supplementary Material for an example of how to read the nomograms.
The xerostomia endpoints were grade 2 (XER\(\geq 2\)) and grade 3 (XER\(\geq 3\)). The bootstrap-validation C-statistic is listed below the included variables.

### DISCUSSION

While the rate of xerostomia is reduced by sparing the parotid glands, a probable contributor to persistent xerostomia could be radiation-induced damage to other salivary glands such as the submandibular glands, sublingual glands and minor salivary glands in the oral cavity. Studies have shown a correlation between the dose to submandibular glands and sticky saliva (19). Some studies have also demonstrated that in selected patients it is safe to try to spare the submandibular glands with IMRT; however, this approach should be used with caution in patients with a significant risk of recurrence, relating to tumor location (20). The impact on xerostomia from minor salivary glands in the oral cavity and oropharynx is difficult to study because of their anatomical dispersion and their poor anatomical definition in the planning image. Data are conflicting regarding the benefit of reducing the dose to these glands (19, 21) but delineation of the oral cavity as an OAR with respect to xerostomia has been recommended in some institutions. In the present analysis, the only OAR considered was the parotid gland since other salivary glands had not been consistently delineated and the corresponding dose is not recorded in the registry. Also, the series of studies by Beetz et al. (19, 22, 23) suggest that the parotid is the main OAR for xerostomia (although using a slightly different definition compared to the present study), by showing that only the dose to the parotids, among the different salivary glands, was a significant predictor of patient-rated xerostomia.

The dose to the contralateral parotid has been studied as a predictor for patient-rated xerostomia (19) and salivary function is largely preserved if at least one parotid receives less than 25 Gy of mean dose (24). Still, there seems to be a benefit of limiting the dose to both parotids (25). Given the uncertainty of the definition of the OAR, both the total parotid volume and the contralateral parotid volume were considered, in different models. These models were very similar but applying the model for the contralateral parotid only, to optimize treatment plans, could be expected to lead to an increase in ipsilateral parotid dose. Such a strategy is not supported by the current study; all patient plans were optimized to spare both parotids as much as the target coverage allowed.

Baseline xerostomia is not uncommon in HNC patients and is predictive of xerostomia after radiotherapy (19, 26). Therefore, patients with baseline xerostomia are often excluded from studies of purely radiation-induced xerostomia. In contrast, the aim of the current study was to develop a model based on real-world data, predicting the risk of xerostomia for the greater population of HNC patients receiving radiotherapy. Therefore, it was not considered appropriate to exclude patients with baseline xerostomia. Baseline scores were also not available for all patients as this assessment has only recently been included in the registry. In future analyses, baseline xerostomia will be considered as a variable in the model. Notably, older age was highly significant in all models, likely as a surrogate for baseline xerostomia, as this is related to age in general and increased medication in particular (8).

Xerostomia is typically assessed by direct measurement of salivary-flow rate, by self-reported questionnaires or by scoring methods, as in the present study. Salivary-flow rates provide important information about salivary gland function and can be performed from each major gland or from a mixed sample of the oral fluids, often termed whole saliva. However, xerostomia is experienced differently by individuals (14) and is not identical to hyposalivation since it also depends on changes in the quality of saliva even with unchanged salivary-flow rate. Therefore patients may complain of dry mouth despite adequate salivation (27). In the current study, the oncologists perceived grade-2 xerostomia (moderately dry) to be less specific than grade 3 and 4 (completely dry and fibrosis, respectively). This may have
contributed to the lower predictive power of the low-grade models; predictions made using the high-grade models are more reliable. However, since grade $\geq 2$ xerostomia is problematic for the patients and relatively prevalent it is important to avoid also grade 2, if possible.

Another factor possibly contributing to the modest predictive power of the models is the variability in the time between radiotherapy and registered follow-up in the cohort. While focusing on a fixed time after treatment was not possible for our data set, this might have improved the performance of the model since there is a time dependence of incidence of xerostomia after treatment (15). As future work we plan to fit a model to a subset of the patients with follow-up data in a limited time interval. As well as revealing the importance of the follow-up time, this will also facilitate comparisons with studies using a fixed follow-up time.

Future work will also explore the significance of HPV status for the risk of xerostomia after radiotherapy. Further, the predictive power may have been limited by the omission of HPV status, the patient-specific chemotherapy dose and alcohol consumption as explanatory variables; the two latter variables were not recorded in the registry and were not available for analysis.

IMRT has been shown to be associated with a lower incidence of severe xerostomia compared to 3D-conformal radiotherapy (14). Still, treatment with IMRT was not selected as an inclusion criterion in the current study since any relationship is expected to be indirect, through its impact on the mean parotid dose. Moreover, it was found that it would have made a very small difference to the model if non-IMRT patients had been excluded. Only age was not included in the XER$_{G\geq 2}$ models; for all other variables, hazard ratios and $p$-values remained similar to those in the presented models. The value of the C statistic reflected a lower model performance when limiting the size of the cohort accordingly.

The physical mean parotid dose was used in this study, i.e., without correcting for fraction size per voxel or different fractionation schedules, since dose-volume histograms were not available for conversion to BED. The sensitivity of the results to this limitation was explored by converting the mean dose values to BED; this differs from the actual mean BED by around 1–15% (according to a comparison for a limited number of patients) since each dose bin was not converted before calculating the mean. It was seen, however, that while the predictive power of the models did not consistently improve they were somewhat sensitive to the representation of dose. Future work is planned to collect dose-volume histograms and refit the model with the dose variables in BED. Other sources of uncertainty in the dose variables are, as mentioned previously, that the small contribution from brachytherapy for 25% of the

![Figure 1](https://example.com/figure1.png)

**FIGURE 1** Calibration plots for the models in Table 2 at 1 year: (A) the D$_{tot}$ model for XER$_{G\geq 2}$, (B) the D$_{contra}$ model for XER$_{G\geq 2}$, (C) the D$_{tot}$ model for XER$_{G\geq 3}$, (D) the D$_{contra}$ model for XER$_{G\geq 3}$. The histogram on the upper $x$ axis represents the frequency distribution of 1 minus the predicted probabilities (c.f. a survival analysis).
TABLE 3 | Hazard ratios and corresponding p-values (in brackets) for the Cox regression multivariate analysis excluding non-consensus variables for the XER\textsubscript{G≥2} models.

| Endpoint | Included variables | Hazard ratio (p-value) | Model: $D_{\text{tot}}$ | Model: $D_{\text{contra}}$
|---|---|---|---|---
| XER\textsubscript{G≥2} Mean parotid dose ($D_{\text{tot}}$ or $D_{\text{contra}}$) | 0.98 (<0.01) | 0.997 (0.68)
| $D_{\text{contra}}$ | – | 0.99 (<0.01)
| Tumor location; reference = oral cavity | | |
| Oropharynx | 1.07 (0.67) | 1.07 (0.67)
| Other | 0.57 (<0.01) | 0.58 (<0.01)
| N stage; reference = 2c | | |
| 0 | 0.58 (<0.01) | 0.62 (0.020)
| 1 | 0.57 (0.014) | 0.61 (0.042)
| 2a/b | 0.69 (0.027) | 0.73 (0.080)
| 3 | 0.31 (0.052) | 0.33 (0.067)
| Concomitant chemotherapy; reference = no | | |
| Cisplatin | 2.02 (<0.01) | 1.98 (<0.01)
| Erbitux | 1.46 (0.011) | 1.42 (0.019)
| Age | 1.02 (<0.01) | 1.02 (<0.01)
| C-statistic (SE) | 0.60 (0.057) | 0.60 (0.057)

The bootstrap-validation C-statistic is listed below the included variables.

The fact that the current study included a large number of patients treated consecutively in our institution made it possible to develop a model more representative for the population it will be applied to, compared to models from controlled clinical trials. The diversity naturally occurring in the population is present in the sample and many relevant variables were candidates for inclusion in the models. By using Cox regression the time factor in the follow-up data was naturally accounted for and the risk of xerostomia can be predicted for different times after treatment. However, as a result of the inherent diversity in the dataset, it was found that the fitted model was very sensitive to small adjustments to the patients included in the analysis, despite the great size of the dataset. It was of particular interest to study the risk of xerostomia as a function of OAR dose, but these relationships were relatively weak, and in the case of grade $\geq 2$ xerostomia an inverse dose-response relationship was found. The latter was unexpected but probably a result of indirect correlations or bias, which are more likely to appear in a dataset from a registry compared to a clinical trial. In line with our results, there are some indications that when patients have been treated with IMRT, resulting in lower parotid dose and steeper dose gradients compared to 3D-conformal radiotherapy, the strong association between xerostomia and mean parotid dose observed historically (22, 30) can be expected to be weaker or completely absent (31, 32). In the current analysis, the inverse dose-response found when forcing the dose variable into the multivariate models for XER\textsubscript{G≥2} made the model unsuitable as a decision support tool and a nomogram was instead produced for a model which did not contain dose. Thus, unlike the nomogram for XER\textsubscript{G≥3}, this cannot be used to guide radiotherapy treatment planning but is nonetheless useful for managing the risk of moderate xerostomia.

Models developed based on real-world data are a valuable complement to controlled clinical trials and are particularly suitable as decision-support tools in a learning healthcare system (16). The analysis of registry data needs to be performed carefully, taking advantage of the heterogeneity of the population while...
Onjukka et al. Modeling Xerostomia Using Registry Data

### FIGURE 3

The predicted risk of grade $\geq 2$ xerostomia at 9, 12, and 24 months after radiotherapy, not including dose, due to the inverse dose-response relationship. Model specifics are listed in Supplementary Table A2 in the Supplementary Material. *Note that the model does not imply significant differences between all categories with respect to the endpoint – the $p$-value only refers to the difference from the reference category (see Supplementary Table A2 for $p$-values). “No” was reference for concomitant chemotherapy and Erbitux was not significantly different from the reference. “N2c” was reference for N stage and N3 was not statistically different. Note that the model does not establish whether there is a difference between N0 and N1. “Oral cavity” was reference for tumor location and oropharynx was not statistically different.

### FIGURE 4

The predicted risk of grade $\geq 3$ xerostomia at 9, 12, and 24 months after radiotherapy, using the $D_{tot}$ dose variable. *Note that not all categories are significantly different from each other with respect to the endpoint – the $p$-value only refers to the difference from the reference category (see Table 2 for $p$-values). “No” was reference for concomitant chemotherapy and Erbitux was not significantly different.

#### Cox regression model: grade $\geq 2$ xerostomia

| Points | 0 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90 | 100 |
|--------|---|----|----|----|----|----|----|----|----|----|-----|
| Concomitant chemotherapy* | Erbitux | No | Cisplatin |
| N stage* | 3 | 1 | 2a | 0 | 2c |
| Tumor location* | Oropharynx | Other | Oral cavity |

#### Total points-to-risk nomogram

| Total points | 100 | 120 | 140 | 160 | 180 | 200 | 220 | 240 |
|-------------|-----|-----|-----|-----|-----|-----|-----|-----|
| Risk at 9 months (%) | 5 | 10 | 15 | 20 | 25 | 30 | 35 | 40 | 45 |
| Risk at 12 months (%) | 5 | 10 | 15 | 20 | 25 | 30 | 35 | 40 | 45 | 50 | 55 |
| Risk at 24 months (%) | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 |

#### Cox regression model: grade $\geq 3$ xerostomia

| Points | 0 | 20 | 40 | 60 | 80 | 100 |
|--------|---|----|----|----|----|-----|
| Age | 25 | 30 | 35 | 40 | 45 | 50 | 55 | 60 | 65 | 70 | 75 | 80 | 85 | 90 | 95 |
| Concomitant chemotherapy* | Erbitux | No | Cisplatin |
| $D_{tot}$ | 0 | 20 | 40 | 60 |

#### Total points-to-risk nomogram

| Total points | 80 | 100 | 120 | 140 | 160 | 180 | 200 |
|-------------|----|-----|-----|-----|-----|-----|-----|
| Risk at 9 months (%) | 0.2 | 0.4 | 0.6 | 0.8 | 1 | 1.5 | 2 | 3 | 4 | 5 | 7 | 9 | 11 |
| Risk at 12 months (%) | 0.2 | 0.4 | 0.6 | 0.8 | 1 | 1.5 | 2 | 3 | 4 | 6 | 8 | 12 |
| Risk at 24 months (% | 0.5 | 1 | 1.5 | 2 | 3 | 4 | 6 | 8 | 10 | 15 | 20 | 25 | 35 |
selecting endpoints, variables and variable parameterization to obtain a useful model. For example, 2c was selected as reference for N stage since it was discovered that this disease stage was associated with a higher risk of xerostomia, even compared to stage 3 (although the prediction for stage 3 could be uncertain, given the few cases included in the dataset and that N3 was not statistically different from N2c as shown by the p-value in Supplementary Table A2). It was speculated that this is related to the bilateral location of involved lymph nodes with N2c. It is also important to not overinterpret the nomogram and assume that all aspects are statistically significant. For example, the model behind the nomogram in Figure 3 does not establish the relationship between N0 and N1, only each category’s difference from the reference category, N2c. There is no reason to suppose that N0 implies a higher risk compared to N1, and the small difference seen in the nomogram is unlikely to result in misleading predictions.

If the model is developed to improve future treatment plans it is important to consider possible mechanisms behind observed relationships, i.e., causality. In the current analysis it was felt that external validation would be required to confirm the lower risk associated with hyperfractionated/accelerated treatment schedules and induction chemotherapy, to rule out false correlations. The only support in the literature for the former is weak given the few patients studied and limited dose-volume information (33). It is hoped that future studies can confirm or dement the causality of these relationships.

**CONCLUSION**

Late xerostomia after radiotherapy can be modeled with reasonable predictive power based on registry data, providing valuable alternatives to models developed on cohorts with stricter inclusion criteria. Similarities with similar models were observed but as the first Cox regression model for xerostomia, some important lessons were learned. The variables included and the performance of the model depend strongly on the grade of the endpoint, the patient selection and the candidate variables considered. The role of the parotid dose may be of lower importance compared to some clinical variables in a heterogeneous population. The results also suggest that an accelerated treatment schedule or induction chemotherapy may be associated with a lower risk of xerostomia, but until this has been confirmed a model excluding these variables can be used. The risk of modeling indirect relationships, given the unavoidably heterogeneous registry data, needs to be carefully considered in the interpretation of the results.

**REFERENCES**

1. Borras JM, Barton M, Grau C, Corral J, Verhoeven R, Lemmens V, et al. The impact of cancer incidence and stage on optimal utilization of radiotherapy: methodology of a population based analysis by the ESTRO-HERO project. *Radiother Oncol.* (2015) 116:45–50. doi: 10.1016/j.radonc.2015.04.021

**DATA AVAILABILITY STATEMENT**

The datasets generated for this study will not be made publicly available. The patients participating in the study have not consented to their data being publicly available.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by the Stockholm Regional Ethics Committee. The patients/participants provided their written informed consent to participate in this study.

**AUTHOR CONTRIBUTIONS**

EO, IL, and CM contributed to the conception and design of the study and interpreted the results together with EB and AE. AB was also involved in the design and interpretation of the statistical methodology and performed the analysis. CM, EB, AE, GA, SF, CL, and HS contributed to the data collection and IL to the registry design and management. GG and SF facilitated the development of the registry and advised on the scientific contents of the study. EO compiled and presented the results. The manuscript was written by EO, IL, and CM. All authors reviewed and approved the manuscript.

**FUNDING**

This study was partly funded by a grant (number 164082) from the King Gustaf V Jubilee Fund (Stockholm, Sweden).

**ACKNOWLEDGMENTS**

The authors are grateful to Dr. Tiziana Rancati (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy) for her advice on outcome modeling techniques.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2020.01647/full#supplementary-material

2. Barnett GC, West CM, Dunning AM, Elliott RM, Coles CE, Pharoah PD, et al. Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype. *Nat Rev Cancer.* (2009) 9:134–42.

3. Langendijk JA, Doornaert P, Verdonck-de Leeuw IM, Leemans CR, Aaronson NK, Slotman BJ. Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy. *J Clin Oncol.* (2008) 26:3770–6.
4. Dirix P, Nuyts S. Evidence-based organ-sparing radiotherapy in head and neck cancer. *Lancet Oncol.* (2010) 11:85–91. doi: 10.1016/s1470-2153(09)70531-1

5. Dirix P, Nuyts S, Van den Bogaert W. Radiation-induced xerostomia in patients with head and neck cancer: a literature review. *Cancer.* (2006) Aug 15;107(2):34.

6. Hamlet S, Faull J, Klein B, Afref A, Fontanesi J, Stachler R, et al. Mastication and swallowing in patients with postirradiation xerostomia. *Int J Radiat Oncol Biol Phys.* (1997) 37:789–96.

7. Logemann JA, Paulsoski BR, Rademaker AW, Lazarus CL, Mittal B, Gazzano J, et al. Xerostomia: 12-month changes in saliva production and its relationship to perception and performance of swallowing function, oral intake, and diet after chemoradiation. *Head Neck.* (2003) 25:432–7.

8. Roh JI, Kim AY, Cho MJ. Xerostomia following radiotherapy of the head and neck affects vocal function. *J Clin Oncol.* (2005) 23:3016–23.

9. Epstein JB, Chiu EA, Jacobson JJ, Rishiraj B, Le N. The relationships among fluoride, cariogenic oral flora, and salivary flow rate during radiation therapy. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod.* (1998) 86:286–92.

10. Villa A, Nordio F, Gohel A. A risk prediction model for xerostomia: a retrospective cohort study. *Gerodontology.* (2016) 33:562–8.

11. Astor FC, Hanft KL, Ciocco JO. Xerostomia: a prevalent condition in the elderly. *Ear Nose Throat J.* (1999) 78:476–9.

12. Thorselius I, Emlison CG, Osterberg T. Salivary conditions and drug consumption in older age groups of elderly Swedish individuals. *Gerodontics.* (1998) 4:66–70.

13. Chambers MS, Garden AS, Rosenthal D, Ahamad A, Schwartz DL, Blanco AI, et al. Intensity-modulated radiotherapy: is xerostomia still prevalent? *Curr Oncol Rep.* (2005) 7:131–6.

14. Nutting CM, Morden JP, Harrington KJ, Urbano TG, Bhide SA, Clark C, et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPECT): a phase 3 multicentre randomised controlled trial. *Lancet Oncol.* (2011) 12:127–36.

15. Brodin NP, Tome WA. Revisiting the dose constraints for head and neck OARs in the current era of IMRT. *Oral Oncol.* (2018) 86:8–18. doi: 10.1016/j.oraloncology.2018.08.018

16. Nakatugawa M, Cheng Z, Kiss A, Cholet A, Bowers M, Utsunomiya K, et al. The needs and benefits of continuous model updates on the accuracy of rt-induced toxicity prediction models within a learning health system. *Int J Radiat Oncol Biol Phys.* (2019) 103:460–7.

17. van der Schaaf A, Langendijk JA, Fiorino C, Rancati T. Embracing volume modeling of salivary function in patients with head-and-neck cancer receiving radiotherapy. *Int J Radiat Oncol Biol Phys.* (2012) 84:S22–3.

18. Neufeld SM, Zaffaroni N, Chen PY, Krauss DJ, Yan D, Martinez A. Adaptive replanning strategies accounting for shrinkage in head and neck imrt. *Int J Radiat Oncol Biol Phys.* (2009) 75:924–32.

19. Jellema AP, Doornaert P, Slotman BJ, Leemans CR, Langendijk JA. Does radiation dose to the salivary glands and oral cavity predict patient-rated xerostomia and sticky saliva in head and neck cancer patients treated with curative radiotherapy? *Radiother Oncol.* (2005) 77:164–71.

20. Gabrys HS, Buettner F, Sterzing F, Hauswald H, Bangert M. Design and selection of machine learning methods using radiomics and dosiomics for normal tissue complication probability modeling of xerostomia. *Front Oncol.* (2018) 8:35.

21. Kaae JK, Johnsen L, Hansen CR, Kristensen MH, Brink C, Eriksen JG. Relationship between patient and physician-rated xerostomia and dose distribution to the oral cavity and salivary glands for head and neck cancer patients after radiotherapy. *Acta Oncol.* (2019) 58:1366–72.

22. Beetz I, Schlütra C, Burlage FR, Koken PW, Doornaert P, Bijl HP, et al. Development of NTCP models for head and neck cancer patients treated with three-dimensional conformal radiotherapy for xerostomia and sticky saliva: the role of dosimetric and clinical factors. *Radiother Oncol.* (2012) 105:86–93. doi: 10.1016/j.radonc.2011.03.010

23. Beetz I, Schlütra C, van Luijk P, Christiaen ME, Doornaert P, Bijl HP, et al. External validation of three dimensional conformal radiotherapy based NTCP models for patient-rated xerostomia and sticky saliva among patients treated with intensity modulated radiotherapy. *Radiother Oncol.* (2012) 105:94–100. doi: 10.1016/j.radonc.2011.11.006

24. Blanco AI, Chao KS, El Naqa I, Franklin GE, Zakarian K, Vicic M, et al. Dose-volume modeling of salivary function in patients with head-and-neck cancer radiotherapy. *Int J Radiat Oncol Biol Phys.* (2005) 62:1055–69.

25. Deasy JO, Moiseenko V, Marks L, Chao KS, Nam J, Eisbruch A. Radiotherapy dose-volume effects on salivary gland function. *Int J Radiat Oncol Biol Phys.* (2010) 76(Suppl. 3):S58–63.

26. Edenrich CM, Henrikson CO, Jakobsson PA. Pre-irradiation qualities of a parotid gland predicting the grade of functional disturbance by radiotherapy. *Acta Otolaryngol.* (1972) 74:436–44.

27. Ship JA, Fox PC, Baum BJ. How much saliva is enough–normal function defined. *J Am Dental Assoc.* (1991) 122:63–9.

28. Lee C, Langen KM, Lu WG, Haimerl J, Schnarr E, Ruchala KJ, et al. Assessment of parotid gland dose changes during head and neck cancer radiotherapy using daily megavoltage computed tomography and deformable image registration. *Int J Radiat Oncol Biol Phys.* (2008) 71:1563–71.

29. Wu QW, Chi YW, Chen PY, Krauss DJ, Yan D, Martinez A. Adaptive replanning strategies accounting for shrinkage in head and neck imrt. *Int J Radiat Oncol Biol Phys.* (2009) 75:924–32.

30. Jellema AP, Doornaert P, Slotman BJ, Leemans CR, Langendijk JA. Does radiation dose to the salivary glands and oral cavity predict patient-rated xerostomia and sticky saliva in head and neck cancer patients treated with curative radiotherapy? *Radiother Oncol.* (2005) 77:164–71.

31. Gabrys HS, Buettner F, Sterzing F, Hauswald H, Bangert M. Design and selection of machine learning methods using radiomics and dosiomics for normal tissue complication probability modeling of xerostomia. *Front Oncol.* (2018) 8:35.

32. Kaae JK, Johnsen L, Hansen CR, Kristensen MH, Brink C, Eriksen JG. Relationship between patient and physician-rated xerostomia and dose distribution to the oral cavity and salivary glands for head and neck cancer patients after radiotherapy. *Acta Oncol.* (2019) 58:1366–72.

33. Leslie MD, Dische S. Parotid gland function following accelerated and conventionally fractionated radiotherapy. *Radiother Oncol.* (1991) 22:133–9.

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Onjukka, Mercke, Björgvinsson, Embring, Berglund, Alexandersson von Döbeln, Friesland, Gagliardi, Lenneby Helleday, Sjödin and Lax. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.